Letter to the editor re: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'. Expert rev clin pharmacol 2020;13(7): 787-96.

Letter to the editor re: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'. Expert rev clin pharmacol 2020;13(7): 787-96. Expert Rev Clin Pharmacol. 2021 Jan 11;: Authors: Sabatine MS, Giugliano RP, Schwartz GG PMID: 33428482 [PubMed - as supplied by publisher]
Source: Expert Review of Clinical Pharmacology - Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research